



GIG
CYMRU
NHS
WALES

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



Canolfan Ganser Felindre
Velindre Cancer Centre

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>

Date: 23rd November 2023

Ref: CORP 2023 - 163

Dear xxxxxxxx

Freedom of Information request: Treatment of renal cell carcinoma and melanoma (CORP 2023-163)

Thank you for your request for information which the Trust received on 10th October 2023.


Your Request:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- *Avelumab + Axitinib*
- *Axinitib*
- *Cabozantinib*
- *Everolimus*
- *Lenvatinib + Everolimus*
- *Nivolumab monotherapy*
- *Nivolumab + Cabozantinib*
- *Nivolumab + Ipilimumab*
- *Pazopanib*
- *Pembrolizumab monotherapy*
- *Pembrolizumab + Axitinib*
- *Pembrolizumab + Lenvatinib*
- *Radiotherapy only*
- *Sunitinib*
- *Temsirolimus*
- *Tivozanib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





GIG
CYMRU
NHS
WALES

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



Canolfan Ganser Felindre
Velindre Cancer Centre

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>

- *Cobimetinib*
- *Dabrafenib*
- *Dabrafenib AND Trametinib*
- *Dacarbazine*
- *Denosumab*
- *Encorafenib AND Binimetinib*
- *Ipilimumab*
- *Ipilimumab AND Nivolumab*
- *Nivolumab*
- *Pembrolizumab*
- *Trametinib*
- *Vemurafenib*
- *Vemurafenib AND Cobimetinib*
- *Other active systemic anti-cancer therapy*
- *Palliative care only*


Q3. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

Please find the Trust's response below:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- **Avelumab + Axitinib**
- **Axitinib**
- **Cabozantinib**
- **Everolimus**
- **Lenvantinib + Everolimus**
- **Nivolumab monotherapy**
- **Nivolumab + Cabozantinib**
- **Nivolumab + Ipilimumab**
- **Pazopanib**
- **Pembrolizumab monotherapy**
- **Pembrolizumab + Axitinib**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





**GIG
CYMRU
NHS
WALES**

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



Canolfan Ganser Felindre
Velindre Cancer Centre

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>


- **Pembrolizumab + Lenvatinib**
- **Radiotherapy only**
- **Sunitinib**
- **Temsirolimus**
- **Tivozanib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Please note patients may be treated with more than one regimen.

| | |
|---|----|
| Avelumab + Axitinib | 6 |
| Axinitib | 0 |
| Cabozantinib | 0 |
| Everolimus | 0 |
| Ipilimumab monotherapy | 0 |
| Lenvatinib + Everolimus | 0 |
| Nivolumab monotherapy | 35 |
| Nivolumab + Cabozantinib | 0 |
| Nivolumab + Ipilimumab | <6 |
| Pazopanib | 0 |
| Pembrolizumab + Axitinib | 0 |
| Pembrolizumab + Lenvatinib | 29 |
| Pembrolizumab monotherapy | 18 |
| Sunitinib | 0 |
| Temsirolimus | 0 |
| Tivozanib | 0 |
| Other active systemic anti-cancer therapy | <6 |
| Palliative | 9 |

Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





**GIG
CYMRU
NHS
WALES**

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



Canolfan Ganser Felindre
Velindre Cancer Centre

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>


Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- **Cobimetinib**
- **Dabrafenib**
- **Dabrafenib AND Trametinib**
- **Dacarbazine**
- **Denosumab**
- **Encorafenib AND Binimetinib**
- **Ipilimumab**
- **Ipilimumab AND Nivolumab**
- **Nivolumab**
- **Pembrolizumab**
- **Trametinib**
- **Vemurafenib**
- **Vemurafenib AND Cobimetinib**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Please note patients may be treated with more than one regimen.

| | |
|---|----|
| Cobimetinib | 0 |
| Dacarbazine | 0 |
| Dabrafenib AND Trametinib | 11 |
| Dacarbazine | <6 |
| Encorafenib AND Binimetinib | 0 |
| Ipilimumab | <6 |
| Ipilimumab AND Nivolumab | 21 |
| Nivolumab | 22 |
| Pembrolizumab | 84 |
| Trametinib | 0 |
| Vemurafenib | 0 |
| Vemurafenib AND Cobimetinib | 0 |
| Other active systemic anti-cancer therapy | 15 |
| Palliative care only | 0 |

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





GIG
CYMRU
NHS
WALES

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Gwasanaeth Gwaed Cymru
Welsh Blood Service

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



Canolfan Ganser Felindre
Velindre Cancer Centre

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>

Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Q3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

The Trust participates in 2 clinical trials for the treatment of renal cell carcinoma:

- Renal Refine – 0 patients.
- MITRE – less than 6.


Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:-

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff / Caerdydd
CF15 7QZ
Tel / Ffon - 029 20196161

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





**GIG
CYMRU
NHS
WALES**

Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



**Gwasanaeth Gwaed Cymru
Welsh Blood Service**

Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ



**Canolfan Ganser Felindre
Velindre Cancer Centre**

Ffôn/Phone : (029) 20196161

<https://velindre.nhs.wales>

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:-

Information Commissioner's Office - Wales

2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Yours sincerely

Lauren Fear

Director of Corporate Governance and Chief of Staff

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

